Cargando…

Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint structural deterioration. Driven by recent expectations that patients in clinical trials randomized to placebo should be ‘rescued’ with active therapy within 6 months of starting treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jansen, Jeroen P., Vieira, Maria-Cecilia, Bradley, John D., Cappelleri, Joseph C., Zwillich, Samuel H., Wallenstein, Gene V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991055/ https://www.ncbi.nlm.nih.gov/pubmed/27538585 http://dx.doi.org/10.1186/s12891-016-1195-4

Ejemplares similares

Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
por: Rendas-Baum, Regina, et al.
Publicado: (2011)

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
por: Strand, Vibeke, et al.
Publicado: (2017)

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
por: Strand, Vibeke, et al.
Publicado: (2015)

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
por: Fleischmann, Roy, et al.
Publicado: (2016)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2016)

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
por: Milici, Anthony J, et al.
Publicado: (2008)

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry
por: Olsen, Inge C, et al.
Publicado: (2019)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
por: Yamanaka, Hisashi, et al.
Publicado: (2016)

The Long-Term Effects of Treating Rheumatoid Arthritis
por: Scott, D. L., et al.
Publicado: (1983)

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Marked deterioration in rheumatoid arthritis associated bronchiectasis following treatment with Rituximab
por: Musameh, K., et al.
Publicado: (2019)

The Treatment of Joints in Rheumatoid Arthritis
por: Lindsay, James
Publicado: (1907)

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States
por: Claxton, Lindsay, et al.
Publicado: (2016)

Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing
por: Farrow, Matthew, et al.
Publicado: (2020)

Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis
por: Bergrath, Evelien, et al.
Publicado: (2017)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
por: Reed, George W., et al.
Publicado: (2019)

Rheumatoid arthritis affecting temporomandibular joint
por: Sodhi, Amandeep, et al.
Publicado: (2015)

Prevalence of Elbow Joint Arthritis and Enthesitis in Rheumatoid Arthritis
por: Schäfer, Valentin Sebastian, et al.
Publicado: (2020)

Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials
por: Rendas-Baum, Regina, et al.
Publicado: (2017)

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6
por: van Vollenhoven, Ronald F., et al.
Publicado: (2018)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab
por: Hirao, M, et al.
Publicado: (2008)

Lower limb joint replacement in rheumatoid arthritis
por: Clement, Nicholas D, et al.
Publicado: (2012)

Impact of Temporomandibular Joint Pain in Rheumatoid Arthritis
por: Ahmed, Neveen, et al.
Publicado: (2013)

Temporomandibular joint disorders in patients with rheumatoid arthritis
por: Sadura-Sieklucka, Teresa, et al.
Publicado: (2021)

Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib
por: Strand, Vibeke, et al.
Publicado: (2020)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

Ultrasound-guided intra-articular triamcinolone acetonide injection for treating refractory small joints arthritis of rheumatoid arthritis patients
por: Wang, Shaokun, et al.
Publicado: (2019)

Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment
por: Heckert, Sascha L, et al.
Publicado: (2023)

Large joints are progressively involved in rheumatoid arthritis irrespective of rheumatoid factor status—results from the early rheumatoid arthritis study
por: Zhao, Sizheng Steven, et al.
Publicado: (2021)

Declining needs for total joint replacements for rheumatoid arthritis
por: Khan, Nasim A, et al.
Publicado: (2011)

Early biomarkers of joint damage in rheumatoid and psoriatic arthritis
por: Mc Ardle, Angela, et al.
Publicado: (2015)

Relationship between handedness and joint involvement in rheumatoid arthritis
por: Yaku, Ai, et al.
Publicado: (2016)

Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis
por: Sabokbar, Afsie, et al.
Publicado: (2017)

The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
por: Incerti, Devin, et al.
Publicado: (2020)

Evaluating associations of joint swelling, joint stiffness and joint pain with physical activity in first-degree relatives of patients with rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA), a prospective cohort study
por: Hughes-Austin, Jan M, et al.
Publicado: (2021)

Goals for rheumatoid arthritis: treating to target or treating to prevent?
por: Yang, Min, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cd7rm1mjur55bkfie8137uhc80